Taylor Swift buys back rights to her first 6 albums
Bryan West, USA Today's Taylor Swift reporter, joins Hanomansing Tonight to discuss the significance of Taylor Swift buying her music back.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
9 minutes ago
- Globe and Mail
What asset mix minimizes your chances of a loss?
No one likes to lose money. But retirees are especially averse to investment losses, since they no longer have a continuing stream of employment earnings. Take Martha, a 65-year-old who expects to live at least until 94 thanks to good genes and a healthy diet. Apart from Canada Pension Plan and Old Age Security pensions, all her retirement income will have to be generated from her savings. She would like to avoid a capital loss, but how? Martha considers three asset mixes: 40/60, meaning 40 per cent in stocks (split evenly between U.S. and Canadian ones), and 60 per cent in long-term government bonds; 20/80; and 0/100, meaning everything in bonds. To improve her chances, she keeps her investment fees low, at 0.5 per cent, by investing in exchange-traded funds (ETFs). Martha's expected retirement period is 29 years, which is convenient for our analysis since there have been exactly three 29-year periods since 1938 (the first year with good statistics for all asset classes). There is a fair chance the future will resemble at least one of those three periods – we just don't know which one. As the chart shows, Martha would have lost money in at least four years out of 29 and as many as eight years. The most benign period investment-wise turned out to be 1996-2024, even though it included the dot-com bubble (which burst in 2000), 9/11 and the Great Recession of 2008-2009. Regardless of the period, we find that Martha could have minimized the risk of a loss by investing at least some assets in stocks. This may come as a surprise since stocks are traditionally considered riskier than bonds. The 20/80 asset mix proved to be the safest, and while the 40/60 mix was a little riskier, it did result in a higher average return. Coming in dead last was the strategy of putting 100 per cent in long-term bonds. If Martha was intent on avoiding a loss under any circumstances, she could have put all her money in a short-term bond fund, a money market fund or GICs. That strategy, however, would have resulted in a lower long-term return than any of the three asset mixes analyzed above. The moral here? Even the most risk-averse retiree needs to accept a little investment risk. Frederick Vettese is former chief actuary of Morneau Shepell and author of the PERC retirement calculator (
Globe and Mail
10 minutes ago
- Globe and Mail
Cardiovascular Tailwind Boosts BSX: Here's How to Play the Stock
Boston Scientific BSX, a prominent global player in cardiovascular technology, is well-positioned to capitalize on the robust expansion of the cardiovascular devices market. According to a MarketsandMarkets report, this market was valued at $72.83 billion in 2023 and is expected to witness a strong CAGR of 7.3% between 2024 and 2029. With its portfolio of Cardiology and Peripheral Interventions products, Boston Scientific is set to benefit significantly from this upward trend. The booming cardiovascular devices market, driven by aging demographics, minimally invasive procedures, and tech innovation, is propelling Boston Scientific's top-line growth, product leadership and stronger profitability. These tailwinds were clearly reflected in the company's robust first-quarter 2025 performance and raised full-year 2025 guidance. In the past year, Boston Scientific's shares have skyrocketed roughly 31.8%, outpacing the broader Medical Product industry and the S&P 500 benchmark, which have improved about 8.9% and 11.9%, respectively. During this time, Boston Scientific has also outpaced key peers such as Abbott Laboratories ABT and Medtronic MDT. While Abbott, known for its structural heart, cardiac rhythm management, and diagnostics products, gained 24.2%, Medtronic, known for heart valves and coronary stents, advanced 5.1%. BSX 1 Year Price Comparison Major Tailwinds Driving BSX Stock Strong Q1: In the first quarter of 2025, Boston Scientific's revenues were up 22.2% on an operational basis (at a constant exchange rate or CER). The Cardiovascular segment sales were up 26.2% year over year. Within this, Cardiology and Peripheral Interventions businesses' sales grew 31.2% and 7.4%, respectively, year over year. U.S. revenues rose 31%, driven by double-digit growth in most business units. Japan and China also delivered strong results, particularly in EP. Boston Scientific reported adjusted earnings per share (EPS) of $0.75, up 34% year over year. The company's revenues and EPS rose due to exceptional top-line growth across key franchises, especially in EP and structural heart, combined with improved margin performance and disciplined cost management. Cardiovascular Steals Spotlight: Boston Scientific's Electrophysiology business is rapidly expanding its global market share, with first-quarter 2025 organic growth surging 145%, positioning BSX as the number two player in the space. This growth is largely driven by strong commercial adoption of FARAPULSE, the company's flagship Pulsed Field Ablation ('PFA') system, which is gaining traction through global demand, new account expansions, and ongoing clinical studies like AVANT GUARD and Elevate PF. Meanwhile, Boston Scientific's structural heart portfolio is also performing well, with WATCHMAN sales up 24% year over year, aided by DRG-enabled procedural growth. Next-gen versions — WATCHMAN FLX and FLX Pro — are accelerating adoption, while trials like CHAMPION-AF and OPTION A aim to expand the device's global market potential. Boston Scientific's 2025 Outlook Looks Promising For full-year 2025, Boston Scientific raised its organic revenue growth guidance to 12- 14% (from 10-12%) and now expects adjusted EPS of $2.87-$2.94, representing 14-17% year-over-year growth. Reported revenue growth is projected at 15-17%, including contributions from recent acquisitions like Axonics and Intera Oncology. Adjusted operating margin is expected to expand 50-75 basis points, driven by strong product mix, notably FARAPULSE and WATCHMAN, and cost efficiencies. Segmentally, Cardiology continues to lead growth, with Endoscopy and Neuromodulation expected to outperform markets and Urology affected modestly by supply constraints. Estimates for BSX Heading North The Zacks Consensus Estimate for Boston Scientific's 2025 sales and EPS implies a year-over-year improvement of 16.4% and 15.9%, respectively. The bottom-line estimates have moved northward in the past 60 days. BSX's Downsides Boston Scientific continues to face a challenging business environment, thanks to industry-wide macroeconomic pressures, including geopolitical tensions, global supply-chain disruptions, and labor market instability. International conflicts and retaliatory trade actions have increased global risks, while volatile financial markets and fluctuating prices for goods and services are squeezing profitability. Sustained macroeconomic pressures may make it more difficult for the company to manage operating expenses effectively. Tariffs are expected to have a $200 million impact in 2025, which, although planned to be offset through sales growth, cost controls and FX benefits, underscores the heightened complexity of the current environment. BSX Stock Valuation With a forward five-year price-to-earnings (P/E) of 33.31X, Boston Scientific's shares are trading at a premium compared with the industry average of 21.29X. It has a Value Score of D at present. P/E Forward Twelve Months (F12M) Meanwhile, MDT's five-year price-to-earnings (P/E) of 15.63X is lower than the industry average. How to Play BSX Stock? Considering Boston Scientific's strong operational performance, leadership in fast-growing cardiovascular segments like Electrophysiology and Structural Heart, and promising pipeline of developments, the company is clearly executing well on both growth and profitability fronts. With projected double-digit revenue and earnings growth, BSX is poised to continue delivering shareholder value, even amid a complex macroeconomic backdrop and tariff headwinds. The stock has excelled both the industry and its peers, and its estimates are likely to continue to trend upward in the near term. Henceforth, the current BSX shareholders may find it prudent to stay invested. Boston Scientific carries a Zacks Rank #3 (Hold) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report
Globe and Mail
10 minutes ago
- Globe and Mail
Onfolio Holdings Inc. Launches Referral Partner Program to Accelerate Adoption of AI Visibility Services
WILMINGTON, Del., June 10, 2025 (GLOBE NEWSWIRE) -- Onfolio Holdings Inc. (Nasdaq: ONFO, ONFOW) (OTCQB: ONFOP) ('Onfolio' or the 'Company') today announced the official launch of its Referral Partner Program to support the rapid growth of its Generative Engine Optimization (GEO) business. The program offers recurring income and long-term upside to professionals who refer clients to Pace Generative LLC, Onfolio's GEO subsidiary, which helps businesses gain visibility in AI-generated answers from tools like ChatGPT, Gemini, Claude, Grok, and Perplexity. For Onfolio, the program should help to capture the demand and scale revenues significantly faster. Generative Engine Optimization (GEO) is a fast-emerging discipline that positions businesses inside AI-generated responses, rather than simply helping them rank in traditional search engines. When prospective clients ask tools like ChatGPT, 'Who's the best cosmetic surgeon in Miami?' or 'Which estate planning firm in NYC is most reputable?', GEO helps to determine whether a business is mentioned in that real-time answer. 'With the way people now search for trusted services, the brands that show up in AI answers will win the next decade,' said Dominic Wells, CEO of Onfolio. 'Our mission is to ensure that great companies don't get left behind - and our referral partners will be essential to helping us scale that impact.' 'AI is now the first stop for answers,' Wells continued. 'If a company isn't cited, it's not just ranked lower, it's invisible. GEO addresses that. And our referral program allows trusted professionals to help their clients while building a new revenue stream for themselves.' For more information about Pace Generative LLC, visit For more information about our referral program, visit or contact Michael Carwile at partners@ About Onfolio Holdings Inc. Onfolio acquires, operates, and scales a diversified portfolio of digital companies. The Company focuses on businesses with strong cash flows, long-term growth potential, and experienced leadership—or those that can be effectively managed by Onfolio's in-house team. By targeting under-optimized businesses with untapped potential, Onfolio adds value through operational expertise, strategic guidance, and advanced technologies. For more information, visit www. Safe Harbor Statement The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words "may," "will," "should," "plans," "explores," "expects," "anticipates," "continues," "estimates," "projects," "intends," and similar expressions. Examples of forward-looking statements include, among others, statements we make regarding expected operating results, such as revenue growth and earnings, and strategy for growth and financial results. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing new customer offerings, changes in customer order patterns, changes in customer offering mix, continued success in technological advances and delivering technological innovations, delays due to issues with outsourced service providers, those events and factors described by us in Item 1.A "Risk Factors" in our most recent Form 10-K and Form 10-Q, other risks to which our Company is subject, and various other factors beyond the Company's control. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
